A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
Public ClinicalTrials.gov record NCT00620594. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Study identification
- NCT ID
- NCT00620594
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 183 participants
Conditions and interventions
Conditions
Interventions
- BEZ235 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 20, 2006
- Primary completion
- Jan 7, 2013
- Completion
- Jan 7, 2013
- Last update posted
- Dec 8, 2020
2006 – 2013
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California at Los Angeles JonssonComprehensiveCancerCtr | Los Angeles | California | 90095 | — |
| Yale University School of Medicine YaleCancerCtr-ClinTrialsOffice | New Haven | Connecticut | 06520 | — |
| Dana Farber Cancer Institute Clinical Trials ProjectManager | Boston | Massachusetts | 02215 | — |
| Nevada Cancer Institute NVCC - Huntsman | Las Vegas | Nevada | 89135 | — |
| Cancer Centers of the Carolinas CCC Faris | Greenville | South Carolina | 29605 | — |
| Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(2) | Nashville | Tennessee | 37203 | — |
| Baylor Health Care System/Sammons Cancer Center Baylor- Sammons | Dallas | Texas | 75246 | — |
| University of Texas/MD Anderson Cancer Center Thoractic Head/Neck Med.Onc(2) | Houston | Texas | 77030-4009 | — |
| Tyler Cancer Center TCC | Tyler | Texas | 75702 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00620594, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 8, 2020 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00620594 live on ClinicalTrials.gov.